Anti-bacterial monoclonal antibodies: next generation therapy against superbugs
The DOI matches its Crossref record; 122 of the 122 references it cites were found in a registry or an index.
Abstract
Prior to the nineteenth century, infectious disease was one of the leading causes of death. Human life expectancy has roughly doubled over the past century as a result of the development of antibiotics and vaccines. However, the emergence of antibiotic-resistant superbugs brings new challenges. The side effects of broad-spectrum antibiotics, such as causing antimicrobial resistance and destroying the normal flora, often limit their applications. Furthermore, the development of new antibiotics has lagged far behind the emergence and spread of antibiotic resistance. On the other hand, the genome complexity of bacteria makes it difficult to create effective vaccines. Therefore, novel therapeutic agents in supplement to antibiotics and vaccines are urgently needed to improve the treatment of infections. In recent years, monoclonal antibodies (mAbs) have achieved remarkable clinical success in a variety of fields. In the treatment of infectious diseases, mAbs can play functions through multiple mechanisms, including toxins neutralization, virulence factors inhibition, complement-mediated killing activity, and opsonic phagocytosis. Toxins and bacterial surface components are good targets to generate antibodies against. The U.S. FDA has approved three monoclonal antibody drugs, and there are numerous candidates in the preclinical or clinical trial stages. This article reviews recent advances in the research and development of anti-bacterial monoclonal antibody drugs in order to provide a valuable reference for future studies in this area. KEY POINTS: • Novel drugs against antibiotic-resistant superbugs are urgently required • Monoclonal antibodies can treat bacterial infections through multiple mechanisms • There are many anti-bacterial monoclonal antibodies developed in recent years and some candidates have entered the preclinical or clinical stages of development.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“More selective alternatives to antibiotics, such as targeted phage therapy or monoclonal antibodies against specific bacteria (Gaborieau et al., 2024; Wang et al., 2022), may also minimize dysbiosis and sustain ICB efficacy.”
From Microbiota-centered interventions to boost immune checkpoint blockade therapies (2025) · cites this paper as Wang et al., 2022
Citations
Cites
Phagocytosis of Microbes: Complexity in Action
Underhill, D. M., & Ozinsky, A. (2002) · Annual Review of Immunology · doi:10.1146/annurev.immunol.20.103001.114744 · Cited by 1,124 · cited 1×
“Activation of complement receptors and FcRs can generate synergistic effects, which are also influenced by other antibody-independent signals, such as Toll-like receptor (TLR) signals (Underhill and Ozinsky 2002).”
BackgroundNovel antibody-antibiotic conjugate eliminates intracellular S. aureus
Lehar, S. M., Pillow, T., Xu, M., Staben, L., Kajihara, K. K., Vandlen, R., DePalatis, L., Raab, H., Hazenbos, W. L., Hiroshi Morisaki, J., et al. (2015) · Nature · doi:10.1038/nature16057 · Cited by 838
Infections of People with Complement Deficiencies and Patients Who Have Undergone Splenectomy
Ram, S., Lewis, L. A., & Rice, P. A. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00048-09 · Cited by 405
Raxibacumab for the Treatment of Inhalational Anthrax
Migone, T.-S., Subramanian, G. M., Zhong, J., Healey, L. M., Corey, A., Devalaraja, M., Lo, L., Ullrich, S., Zimmerman, J., Chen, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810603 · Cited by 294
A multifunctional bispecific antibody protects against Pseudomonas aeruginosa
DiGiandomenico, A., Keller, A. E., Gao, C., Rainey, G. J., Warrener, P., Camara, M. M., Bonnell, J., Fleming, R., Bezabeh, B., Dimasi, N., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009655 · Cited by 277
Moayeri, M., Leppla, S. H., Vrentas, C., Pomerantsev, A. P., & Liu, S. (2015) · Annual Review of Microbiology · doi:10.1146/annurev-micro-091014-104523 · Cited by 262
Satlin, M. J., Chen, L., Patel, G., Gomez-Simmonds, A., Weston, G., Kim, A. C., Seo, S. K., Rosenthal, M. E., Sperber, S. J., Jenkins, S. G., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02349-16 · Cited by 252
Di Bella, S., Ascenzi, P., Siarakas, S., Petrosillo, N., & Di Masi, A. (2016) · Toxins · doi:10.3390/toxins8050134 · Cited by 248
Mishra, M., Byrd, M. S., Sergeant, S., Azad, A. K., Parsek, M. R., McPhail, L., Schlesinger, L. S., & Wozniak, D. J. (2012) · Cellular Microbiology · doi:10.1111/j.1462-5822.2011.01704.x · Cited by 243
ADAM10 Mediates Vascular Injury Induced by Staphylococcus aureus α-Hemolysin
Powers, M. E., Kim, H. K., Wang, Y., & Bubeck Wardenburg, J. (2012) · The Journal of Infectious Diseases · doi:10.1093/infdis/jis192 · Cited by 199
Hua, L., Hilliard, J. J., Shi, Y., Tkaczyk, C., Cheng, L. I., Yu, X., Datta, V., Ren, S., Feng, H., Zinsou, R., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02190-13 · Cited by 181
Type 3 secretion system of Pseudomonas aeruginosa
Horna, G., & Ruiz, J. (2021) · Microbiological Research · doi:10.1016/j.micres.2021.126719 · Cited by 167 · cited 2×
“T3SS plays a key role in the pathogenicity of P. aeruginosa, as it is associated with cer tain antibiotic resistance character istics and has a direct impact on clinical presentation and patient outcomes (Horna and Ruiz 2021).”
BackgroundStaben, L. R., Koenig, S. G., Lehar, S. M., VANDLEN, R. L., Zhang, D., Chuh, J., Yu, S., Ng, C., Guo, J., Liu, Y., et al. (2016) · Nature Chemistry · doi:10.1038/nchem.2635 · Cited by 164
Cross-specificity of protective human antibodies against Klebsiella pneumoniae LPS O-antigen
Rollenske, T., Szijártó, V., Łukasiewicz, J., Guachalla, L. M., Stojkovic, K., Hartl, K., Stulik, L., Kocher, S., Lasitschka, F., Al‐Saeedi, M., et al. (2018) · Nature Immunology · doi:10.1038/s41590-018-0106-2 · Cited by 162
Orth, P., Xiao, L., Hernandez, L. D., Reichert, P., Sheth, P. R., Beaumont, M., Yang, X., Murgolo, N., Ermakov, G., DiNunzio, E., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.560748 · Cited by 160
Monoclonal Antibodies as an Antibacterial Approach Against Bacterial Pathogens
Zurawski, D. V., & McLendon, M. K. (2020) · Antibiotics · doi:10.3390/antibiotics9040155 · Cited by 153 · cited 2×
“And these mAb products can potentially be used to prevent infections as prophylactics (Zurawski and McLendon 2020).”
BackgroundAntibody–Antibiotic Conjugates: A Novel Therapeutic Platform against Bacterial Infections
Mariathasan, S., & Tan, M. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.12.008 · Cited by 146 · cited 1×
“2019; Mariathasan and Tan 2017; Wang-Lin et al.”
Taking aim at wall teichoic acid synthesis: new biology and new leads for antibiotics
Sewell, E. W., & Brown, E. D. (2013) · The Journal of Antibiotics · doi:10.1038/ja.2013.100 · Cited by 143 · cited 1×
“The antibody component specifically binds to N-acetylglucosamine (GlcNAc) of wall teichoic acid (WTA), a key factor for bacteria colonization, peptidoglycan synthesis, and antibiotic resistance (Sewell and Brown 2014).”
BackgroundRouha, H., Badarau, A., Visram, Z. C., Battles, M. B., Prinz, B., Magyarics, Z., Nagy, G., Mirkina, I., Stulik, L., Zerbs, M., et al. (2015) · mAbs · doi:10.4161/19420862.2014.985132 · Cited by 143
Monoclonal antibody-based therapies for bacterial infections
Motley, M. P., Banerjee, K., & Fries, B. C. (2019) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000539 · Cited by 134 · cited 2×
“First, we lack suitable in vitro research models and in vivo animal models that mimic clinical conditions, so the results of internal and external studies of clinical antecedents cannot be transferred to human trials (Motley et al. 2019).”
BackgroundBacterial outer membrane proteins assemble via asymmetric interactions with the BamA β-barrel
Doyle, M. T., & Bernstein, H. D. (2019) · Nature Communications · doi:10.1038/s41467-019-11230-9 · Cited by 132 · cited 1×
“BamA is a critical component of the assembly mechanism of β-barrel structures involved in the insertion and secretion of membrane proteins in bacteria and organelles (Chaturvedi and Mahalakshmi 2017; Doyle and Bernstein 2019).”
BackgroundCerca, N., Jefferson, K. K., Maira-Litrán, T., Pier, D. B., Kelly-Quintos, C., Goldmann, D. A., Azeredo, J., & Pier, G. B. (2007) · Infection and Immunity · doi:10.1128/iai.00078-07 · Cited by 126
Milla, C. E., Chmiel, J. F., Accurso, F. J., VanDevanter, D. R., Konstan, M. W., Yarranton, G. T., Geller, D. E., & for the KB001 Study Group (2013) · Pediatric Pulmonology · doi:10.1002/ppul.22890 · Cited by 125
Kelly‐Quintos, C., Cavacini, L. A., Posner, M. R., Goldmann, D. A., & Pier, G. B. (2006) · Infection and Immunity · doi:10.1128/iai.74.5.2742-2750.2006 · Cited by 121
Kane, T., Carothers, K. E., & Lee, S. W. (2018) · Current Drug Targets · doi:10.2174/1389450117666161128123536 · Cited by 121
Staphylococcus aureus α toxin potentiates opportunistic bacterial lung infections
Cohen, T. S., Hilliard, J. J., Jones-Nelson, O., Keller, A. E., O’Day, T., Tkaczyk, C., DiGiandomenico, A., Hamilton, M., Pelletier, M., Wang, Q., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad9922 · Cited by 119
Warrener, P., Varkey, R., Bonnell, J. C., DiGiandomenico, A., Camara, M., Cook, K., Peng, L., Zha, J., Chowdury, P., Sellman, B., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02643-14 · Cited by 118
Protein A-Specific Monoclonal Antibodies and Prevention of Staphylococcus aureus Disease in Mice
Kim, H. K., Emolo, C., DeDent, A. C., Falugi, F., Missiakas, D. M., & Schneewind, O. (2012) · Infection and Immunity · doi:10.1128/iai.00230-12 · Cited by 116 · cited 3×
“Kim et al. isolated mAbs against nontoxigenic staphylococcal protein A (SpAKKAA), and found that they can block the binding of SpAKKAA immunoglobulin binding domains (IgBDs) to IgGs (Kim et al.”
BackgroundInfluentialRemembering Emil von Behring: from Tetanus Treatment to Antibody Cooperation with Phagocytes
Kaufmann, S. H. E. (2017) · mBio · doi:10.1128/mbio.00117-17 · Cited by 109 · cited 1×
“Emil Adolf von Behring and Erich Wernicke developed the first diphtheria antitoxin serum in 1890 (Kaufmann 2017).”
BackgroundJain, R., Beckett, V. V., Konstan, M. W., Accurso, F. J., Burns, J. L., Mayer-Hamblett, N., Milla, C., VanDevanter, D. R., & Chmiel, J. F. (2018) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2017.12.006 · Cited by 108
Pennini, M. E., Marco, A. D., Pelletier, M. R., Bonnell, J. C., Cvitkovic, R., Beltramello, M., Cameroni, E., Bianchi, S., Zatta, F., Wei, Z., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-02223-7 · Cited by 103
Pier, G. B., Boyer, D. M., Preston, M. J., Coleman, F. T., Llosa, N. J., Mueschenborn-Koglin, S., Theilacker, C., Goldenberg, H. B., Uchin, J., Priebe, G. P., et al. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.9.5671 · Cited by 101
Antibodies in infectious diseases: polyclonals, monoclonals and niche biotechnology
Berry, J. D., & Gaudet, R. G. (2011) · New Biotechnology · doi:10.1016/j.nbt.2011.03.018 · Cited by 101 · cited 1×
“Monoclonal antibodies (mAbs) have lower variability, higher specificity, and less cross-reaction with host cells and normal flora than polyclonal antisera (Berry and Gaudet 2011; Luciani and Iannetti 2017; Zurawski and McLendon 2020).”
BackgroundFrançois, B., Jafri, H. S., Chastre, J., Sánchez-García, M., Eggimann, P., Dequin, P.-F., Huberlant, V., Viña Soria, L., Boulain, T., Bretonnière, C., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30995-6 · Cited by 94
Antibody-Based Immunotherapy To Treat and Prevent Infection with Hypervirulent Klebsiella pneumoniae
Diago-Navarro, E., Calatayud-Baselga, I., Sun, D., Khairallah, C., Mann, I., Ulacia-Hernando, A., Sheridan, B., Shi, M., & Fries, B. C. (2017) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00456-16 · Cited by 90
Diago‐Navarro, E., Motley, M. P., Ruiz‐Pérez, G., Yu, W., Austin, J., Seco, B. M. S., Xiao, G., Chikhalya, A., Seeberger, P. H., & Fries, B. C. (2018) · mBio · doi:10.1128/mbio.00091-18 · Cited by 90 · cited 1×
“1 3 effectively, increase the extracellular lethality of NETs, and reduce bacteria diffusion (Diago-Navarro et al. 2018).”
BackgroundMazumdar, S. (2009) · mAbs · doi:10.4161/mabs.1.6.10195 · Cited by 90 · cited 1×
“PA promotes the binding of LF and EF to the anthrax toxin receptor (ATR) or capillary morphogenesis protein 2 (CMG2) on the surface of mammalian cell, hence exerting cytotoxicity (Mazumdar 2009).”
BackgroundZhou, C., Lehar, S. M., Gutierrez, J., Rosenberger, C. M., Ljumanovic, N., Dinoso, J. B., Koppada, N., Hong, K., Baruch, A., Carrasco‐Triguero, M., et al. (2016) · mAbs · doi:10.1080/19420862.2016.1229722 · Cited by 89
Wang, Q., Chang, C.-S., Pennini, M. E., Pelletier, M. R., Rajan, S., Zha, J., Chen, Y., Cvitkovic, R., Sadowska, A., Thompson, J. H., et al. (2016) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiw021 · Cited by 86
Hua, L., Cohen, T. S., Shi, Y., Datta, V., Hilliard, J. J., Tkaczyk, C., Suzich, J., Stover, C. K., & Sellman, B. R. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00510-15 · Cited by 84
Varshney, A. K., Kuzmicheva, G. A., Lin, J., Sunley, K. M., Bowling, R. A., Kwan, T.-Y., Mays, H. R., Rambhadran, A., Zhang, Y., Martin, R. L., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0190537 · Cited by 84 · cited 2×
“Animal experiments demonstrated that 514G3 has protective activity against lethal bacteremia and is synergistic with vancomycin (Rello et al. 2019; Varshney et al. 2018).”
BackgroundWhere are we with monoclonal antibodies for multidrug-resistant infections?
McConnell, M. J. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.03.002 · Cited by 84 · cited 3×
“The Fc region of antigen-bound antibodies can bind to C1q, thereby triggering the classical complement pathway to lyse bacteria through the formation of a membrane attack complex (MAC) (McConnell 2019; Natali et al.”
BackgroundMechanisms of Neutralization of a Human Anti-α-toxin Antibody
Oganesyan, V., Peng, L., Damschroder, M. M., Cheng, L., Sadowska, A., Tkaczyk, C., Sellman, B. R., Wu, H., & Dall'Acqua, W. F. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.601328 · Cited by 83
Therapeutic Monoclonal Antibodies
Yamada, T. (2011) · The Keio Journal of Medicine · doi:10.2302/kjm.60.37 · Cited by 78 · cited 2×
“The antisera, obtained by immunizing a horse with Corynebacterium diphtheriae or Clostridium tetanus toxin, were effective on patients with diphtheria or tetanus, respectively (Todoroki et al. 2018; Yamada 2011).”
BackgroundPolio endgame: the global introduction of inactivated polio vaccine
Patel, M. M., Zipursky, S., Orenstein, W., Garon, J. R., & Zaffran, M. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2015.1001750 · Cited by 78
Antibody-Mediated Killing of Carbapenem-Resistant ST258 Klebsiella pneumoniae by Human Neutrophils
Kobayashi, S. D., Porter, A. R., Freedman, B. A., Pandey, R., Chen, L., Kreiswirth, B. N., & DeLeo, F. R. (2018) · mBio · doi:10.1128/mbio.00297-18 · Cited by 69 · cited 1×
“Studies also demonstrated that ST258-CPS2 is a viable target for immunoprophylaxis and immunotherapy (Kobayashi et al. 2018).”
BackgroundSkurnik, D., Merighi, M., Grout, M., Gadjeva, M. G., Maira‐Litrán, T., Ericsson, M., Goldmann, D. A., Huang, S. S., Datta, R., Lee, J. C., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci42748 · Cited by 68
Patel, A., DiGiandomenico, A., Keller, A. E., Smith, T. R. F., Park, D. H., Ramos, S., Schultheis, K., Elliott, S. T. C., Mendoza, J., Broderick, K. E., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00576-7 · Cited by 68
Ortines, R. V., Liu, H., Cheng, L., Cohen, T. S., Lawlor, H. A., Gami, A., Wang, Y., Dillen, C. A., Archer, N. K., Miller, R. J., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02288-17 · Cited by 65 · cited 1×
“Treatment with anti-AT mAb successfully reduced wound size and bacterial burden and accelerated epithelial remodeling and wound healing (Ortines et al. 2018).”
BackgroundZeng, H., Yang, F., Feng, Q., Zhang, J., Gu, J., Jing, H., Cai, C., Xu, L., Yang, X., Xia, X., et al. (2020) · Vaccines · doi:10.3390/vaccines8010134 · Cited by 65
Lê, H., Arnoult, C., Dé, E., Schapman, D., Galas, L., Cerf, D. L., & Karakasyan, C. (2020) · Biomacromolecules · doi:10.1021/acs.biomac.1c00082 · Cited by 65
Navalkele, B. D., & Chopra, T. (2018) · Biologics · doi:10.2147/btt.s127099 · Cited by 64 · cited 4×
“Bezlotoxumab could prevent intestinal epithelial damage and colitis by directly neutralizing the toxin (Navalkele and Chopra 2018), facilitate intestinal microflora reconstitution, and reduce the risk of C. difficile infection (CDI) recurrence (Kufel et al.”
BackgroundInfluentialAnthrax toxin: structures, functions and tumour targeting
Liu, S., Schubert, R. L., Bugge, T. H., & Leppla, S. H. (2003) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.3.5.843 · Cited by 59
Transmembrane β-barrels: Evolution, folding and energetics
Chaturvedi, D., & Mahalakshmi, R. (2017) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2017.09.020 · Cited by 58 · cited 1×
“BamA is a critical component of the assembly mechanism of β-barrel structures involved in the insertion and secretion of membrane proteins in bacteria and organelles (Chaturvedi and Mahalakshmi 2017; Doyle and Bernstein 2019).”
BackgroundEngineered human antibodies for the opsonization and killing of Staphylococcus aureus
Chen, X., Schneewind, O., & Missiakas, D. M. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2114478119 · Cited by 58
Skurnik, D., Kropec, A., Roux, D., Theilacker, C., Huebner, J., & Pier, G. B. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis624 · Cited by 57
Uppuluri, P., Lin, L., Alqarihi, A., Luo, G., Youssef, E. G., Alkhazraji, S., Yount, N. Y., Ibrahim, B. A., Bolaris, M. A., Edwards, J. E., et al. (2018) · PLOS Pathogens · doi:10.1371/journal.ppat.1007056 · Cited by 57 · cited 1×
“baumannii) antigens in three-dimensional structure and epitopes (Uppuluri et al. 2018).”
BackgroundProtein A-neutralizing monoclonal antibody protects neonatal mice against Staphylococcus aureus
Thammavongsa, V., Rauch, S., Kim, H. K., Missiakas, D. M., & Schneewind, O. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.11.051 · Cited by 55
The bactericidal effect of a complement-independent antibody is osmolytic and specific to Borrelia
LaRocca, T. J., Holthausen, D. J., Hsieh, C., Renken, C. W., Mannella, C. A., & Benach, J. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0901858106 · Cited by 54
Szijártó, V., Guachalla, L. M., Hartl, K., Varga, C., Badarau, A., Mirkina, I. I., Visram, Z., Stulik, L., Power, C., Nagy, E., et al. (2017) · Virulence · doi:10.1080/21505594.2017.1279778 · Cited by 54
de Vor, L., van Dijk, B., van Kessel, K. P. M., Kavanaugh, J. S., de Haas, C. J. C., Aerts, P. C., Viveen, M. C., Boel, E. C. H., Fluit, A. C., Kwiecinski, J. M., et al. (2022) · eLife · doi:10.7554/elife.67301 · Cited by 54
Yamamoto, B., Shadiack, A. M., Carpenter, S., Sanford, D., Henning, L. N., Gonzales, N., O'Connor, E., Casey, L. S., & Serbina, N. V. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01102-16 · Cited by 49
Le, H. N., Quetz, J. D. S., Tran, V. G., Le, V. T. M., Aguiar-Alves, F., Pinheiro, M. G., Cheng, L., Yu, L., Sellman, B. R., Stover, C. K., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02565-17 · Cited by 49
Badarau, A., Rouha, H., Malafa, S., Battles, M. B., Walker, L., Nielson, N., Dolezilkova, I., Teubenbacher, A., Banerjee, S., Maierhofer, B., et al. (2016) · mAbs · doi:10.1080/19420862.2016.1215791 · Cited by 48
Anti-Psl Targeting of Pseudomonas aeruginosa Biofilms for Neutrophil-Mediated Disruption
Ray, V. A., Hill, P. J., Stover, C. K., Roy, S., Sen, C. K., Yu, L., Wozniak, D. J., & DiGiandomenico, A. (2017) · Scientific Reports · doi:10.1038/s41598-017-16215-6 · Cited by 48
Antibody-Enabled Antimicrobial Nanocapsules for Selective Elimination of Staphylococcus aureus
Ivanova, K., Ivanova, A., Ramon, E., Hoyo, J., Sánchez-Gómez, S., & Tzanov, T. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c09364 · Cited by 48 · cited 2×
“2020) and nanocapsules containing antibacterial essential oil (EO NCs) (Ivanova et al.”
BackgroundDeng, R., Zhou, C., Li, D., Cai, H., Sukumaran, S., Carrasco‐Triguero, M., Saad, O. M., Nazzal, D., Lowe, C., Ramanujan, S., et al. (2019) · mAbs · doi:10.1080/19420862.2019.1627152 · Cited by 46
Targeting Pili in Enterococcal Pathogenesis
Pinkston, K. L., Singh, K. V., Gao, P., Wilganowski, N. L., Robinson, H., Ghosh, S. C., Azhdarinia, A., Sevick-Muraca, E. M., Murray, B. E., & Harvey, B. R. (2014) · Infection and Immunity · doi:10.1128/iai.01403-13 · Cited by 45
Engineering therapeutic antibodies to combat infectious diseases
Wagner, E. K., & Maynard, J. A. (2018) · Current Opinion in Chemical Engineering · doi:10.1016/j.coche.2018.01.007 · Cited by 45 · cited 2×
“FDA has only approved three mAbs to treat bacteria (Wagner and Maynard 2018).”
BackgroundPotent Killing of Pseudomonas aeruginosa by an Antibody-Antibiotic Conjugate
Kajihara, K. K., Pantua, H., Hernández-Barry, H., Hazen, M., Deshmukh, K., Chiang, N., Ohri, R. V., Castellanos, E. R., Martin, L., Matsumoto, M. L., et al. (2021) · mBio · doi:10.1128/mbio.00202-21 · Cited by 45
Anti-bacterial Monoclonal Antibodies
Nagy, E., Nagy, G., Power, C., Badarau, A., & Szijártó, V. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-72077-7_7 · Cited by 44 · cited 2×
“Therefore, targets with high abundance or high topical density, such as polymeric carbohydrate antigens, appear beneficial for initiating the complement pathway (Nagy et al. 2017).”
BackgroundStorek, K. M., Vij, R., Sun, D., Smith, P. A., Koerber, J. T., & Rutherford, S. T. (2018) · Journal of Bacteriology · doi:10.1128/jb.00517-18 · Cited by 44 · cited 1×
“coli strains with truncated LPS by inducing periplasmic stresses and destroying the outer membrane integrity (Storek et al. 2019; Vij et al. 2018).”
BackgroundWang, Y., Kern, A., Boatright, N. K., Schiller, Z. A., Sadowski, A., Ejemel, M., Souders, C. A., Reimann, K. A., Hu, L. T., Thomas, W. D., et al. (2016) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiw151 · Cited by 43
Specific Antibody Deficiencies in Clinical Practice
Sorensen, R. U., & Edgar, D. (2019) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2019.01.024 · Cited by 43 · cited 4×
“Antitoxin antibodies can block the binding of toxins to receptors (Sorensen and Edgar 2019), prevent the toxin’s necessary structural changes for toxicity (Sadarangani 2018), and form immune complexes that assist toxin clearance (Takahashi et al.”
BackgroundInfluentialYi-long, Y., Qian, M., Yi, S., Liu, S., Li, B. J., Yu, R., Guo, Q., Zhang, X., Yu, C., Li, J., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0149460 · Cited by 42 · cited 1×
“Prophylactic administration of 2H7 significantly reduced the intraperitoneal abscess formation in mice suffering from the abdominal infection, and therapeutic administration showed an excellent protective effect in septic mice (Yang et al. 2016).”
BackgroundRoux, D., Pier, G. B., & Skurnik, D. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks335 · Cited by 41
Staphylococcus aureus Pore-Forming Toxins
Robles, T. R., & Torres, V. J. (2016) · Current topics in microbiology and immunology · doi:10.1007/82_2016_16 · Cited by 41 · cited 1×
“The β-barrel pore-forming toxin is capable of destroying cell adhesion junctions of epithelial barriers, altering intracellular signal transduction processes, regulating host immune response, and killing eukaryotic and non-immune cells (Reyes-Robles and Torres 2017).”
BackgroundProtection Against Invasive Infections in Children Caused by Encapsulated Bacteria
Sadarangani, M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02674 · Cited by 41 · cited 1×
“Antitoxin antibodies can block the binding of toxins to receptors (Sorensen and Edgar 2019), prevent the toxin’s necessary structural changes for toxicity (Sadarangani 2018), and form immune complexes that assist toxin clearance (Takahashi et al.”
BackgroundAlternatives to antibiotics in an era of difficult-to-treat resistance: new insights
Rello, J., Parisella, F. R., & Perez, A. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1619454 · Cited by 40
Anti-MrkA Monoclonal Antibodies Reveal Distinct Structural and Antigenic Features of MrkA
Wang, Q., Chen, Y., Cvitkovic, R., Pennini, M. E., Chang, C. S., Pelletier, M. R., Bonnell, J. C., Koksal, A. C., Wu, H., Dall’Acqua, W. F., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0170529 · Cited by 38 · cited 1×
“However, they did not observe any further synergism when different antibodies were used in combination (Wang et al. 2017).”
BackgroundBezlotoxumab: A Novel Agent for the Prevention of Recurrent Clostridium difficile Infection
Kufel, W. D., Devanathan, A. S., Marx, A. H., Weber, D. J., & Daniels, L. M. (2017) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1990 · Cited by 37
Vij, R., Lin, Z., Chiang, N., Vernes, J.-M., Storek, K. M., Park, S., Chan, J., Meng, Y. G., Comps‐Agrar, L., Luan, P., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-25609-z · Cited by 37
Bugg, T. D. H., Rodolis, M. T., Mihalyi, A., & Jamshidi, S. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.03.018 · Cited by 36
de Vor, L., van Dijk, B., van Kessel, K. P. M., Kavanaugh, J. S., de Haas, C. J. C., Aerts, P. C., Viveen, M. C., Boel, E. C. H., Fluit, A. C., Kwiecinski, J. M., et al. (2022) · Utrecht University Repository (Utrecht University) · Cited by 36
Leysath, C. E., Monzingo, A. F., Maynard, J. A., Barnett, J., Georgiou, G., Iverson, B. L., & Robertus, J. D. (2009) · Journal of Molecular Biology · doi:10.1016/j.jmb.2009.02.003 · Cited by 35
Yamamoto, B., Shadiack, A. M., Carpenter, S., Sanford, D., Henning, L. N., O'Connor, E., Gonzales, N., Mondick, J. T., French, J., Stark, G. V., et al. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00972-16 · Cited by 35
Aguilar, J. L., Varshney, A. K., Pechuan-Jorge, X., Dutta, K., Nosanchuk, J. D., & Fries, B. C. (2016) · Virulence · doi:10.1080/21505594.2016.1231295 · Cited by 35
Hot topics in necrotising skin and soft tissue infections
Saeed, K., Esposito, S., Gould, I., Ascione, T., Bassetti, M., Bonnet, E., Bouza, E., Chan, M., Davis, J. S., De Simone, G., et al. (2018) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2018.02.012 · Cited by 35
Todoroki, K., Yamada, T., Mizuno, H., & Toyo’oka, T. (2018) · Analytical Sciences · doi:10.2116/analsci.17r003 · Cited by 35
LaRocca, T. J., Katona, L. I., Thanassi, D. G., & Benach, J. L. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.9.6222 · Cited by 34
Glycosylation-dependent opsonophagocytic activity of staphylococcal protein A antibodies
Chen, X., Shi, M., Tong, X., Kim, H. K., Wang, L., Schneewind, O., & Missiakas, D. M. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2003621117 · Cited by 33 · cited 2×
“reported that 3F6-hIgG1 could bind and neutralize SpA to trigger C1q recruitment and OPK for Staphylococci (Chen et al. 2020).”
BackgroundTakahashi, T., Joshi, S. G., Al‐Saleem, F. H., Ancharski, D. M., Singh, A., Nasser, Z., & Simpson, L. L. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.02.051 · Cited by 30
Human scFvs That Counteract Bioactivities of Staphylococcus aureus TSST-1
Rukkawattanakul, T., Sookrung, N., Seesuay, W., Onlamoon, N., Diraphat, P., Chaicumpa, W., & Indrawattana, N. (2017) · Toxins · doi:10.3390/toxins9020050 · Cited by 29
Altai, M., Liu, H., Orlova, A., Максимилианович, Т. В., & Gräslund, T. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3614 · Cited by 28
Shokri, R., Salouti, M., & Zanjani, R. S. (2015) · The Journal of Microbiology · doi:10.1007/s12275-015-4519-4 · Cited by 28 · cited 1×
“In vitro studies confirmed its targeting effect, and in vivo experiments on mouse models revealed that the GNRs have a protective effect when combined with near-infrared laser energy (Shokri et al. 2015).”
BackgroundTkaczyk, C., Семенова, Е. А., Shi, Y., Rosenthal, K., Oganesyan, V., Warrener, P., Stover, C. K., & Sellman, B. R. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01033-18 · Cited by 28
Motley, M. P., Diago‐Navarro, E., Banerjee, K., Inzerillo, S., & Fries, B. C. (2020) · mBio · doi:10.1128/mbio.02059-20 · Cited by 28 · cited 1×
“In contrast, the mIgG1 improved macrophage-mediated phagocytosis marginally (Motley et al. 2020).”
BackgroundSchiller, Z. A., Rudolph, M. J., Toomey, J. R., Ejemel, M., LaRochelle, A., Davis, S. A., Lambert, H. S., Kern, A., Tardo, A. C., Souders, C. A., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci144843 · Cited by 28
Fighting Antibiotic-Resistant Klebsiella pneumoniae with “Sweet” Immune Targets
Adamo, R., & Margarit, I. (2018) · mBio · doi:10.1128/mbio.00874-18 · Cited by 26 · cited 5×
“Later, they proposed two IgG3 antibodies against CPS2: 17H12 and 8F12, and demonstrated their broad opsonophagocytic killing efficacy in a murine intratracheal infection model.”
InfluentialYoussef, E. G., Alkhazraji, S., Ghebremariam, T., Zhang, L., Singh, S., Yount, N. Y., Yeaman, M. R., Uppuluri, P., & Ibrahim, A. S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00076 · Cited by 26
Girard, B., Beck, K., Dyer, D. N., Mattix, M. E., Twenhafel, N. A., & Nalça, A. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04593-14 · Cited by 22
Pharmacokinetics and Tolerability of Obiltoxaximab: A Report of 5 Healthy Volunteer Studies
Nagy, C. F., Leach, T. S., Hoffman, J. H., Czech, A., Carpenter, S., & Guttendorf, R. J. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.07.170 · Cited by 22
Zhou, C., Cai, H., Baruch, A., Lewin‐Koh, N., Yang, M., Guo, F., Xu, D., Deng, R., Hazenbos, W. L. W., & Kamath, A. V. (2019) · PLoS ONE · doi:10.1371/journal.pone.0224096 · Cited by 21 · cited 1×
“AAC and antibody-conjugated nanoparticles may be promising strategies for combining antibodies and antibiotics (Deng et al. 2019; Mariathasan and Tan 2017; Wang-Lin et al. 2018; Zhou et al. 2019).”
BackgroundHenning, L. N., Carpenter, S., Stark, G. V., & Serbina, N. V. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01590-17 · Cited by 19
Evaluation of Reactivity of Monoclonal Antibodies Against Omp25 of Brucella spp.
Yang, X., He, Z., Zhang, G., Lu, J., Zhang, H., Ren, H., Tian, Y., Yang, H., Chen, C., Li, L., et al. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00145 · Cited by 19 · cited 1×
“They found that mAbs against Omp25 contributed significantly to the detection of Brucella in clinical samples, and mAb 6C12 could potentially be utilized to the therapeutic efficacy of monitor brucellosis (Yang et al. 2020).”
BackgroundAl-Sharqi, A. A., Apun, K., Vincent, M., Kanakaraju, D., Bilung, L. M., & Sum, M. S. H. (2019) · Journal of Applied Microbiology · doi:10.1111/jam.14471 · Cited by 18
Zhou, T., Yue, Y., Zheng, F., Liang, X., Cao, Q., Wang, Y.-W., & Zhu, J. (2019) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2019.08.019 · Cited by 18 · cited 1×
“aureus invading and adhering to host cell and reduced the bacterial burden in the infected mice’s blood (Zhou et al. 2021).”
BackgroundKarau, M. J., Tilahun, M. E., Krogman, A., Osborne, B. A., Goldsby, R. A., David, C. S., Mandrekar, J. N., Patel, R., & Rajagopalan, G. (2016) · Virulence · doi:10.1080/21505594.2016.1267894 · Cited by 17
Lin, S. X. W., Zhou, C., Kamath, A. V., Hong, K., Koppada, N., Saad, O. M., Carrasco‐Triguero, M., Khojasteh, S. C., & Deng, R. (2018) · mAbs · doi:10.1080/19420862.2018.1494478 · Cited by 17
Zeng, H., Zhang, J., Song, X., Zeng, J., Yuan, Y., Chen, Z., Xu, L., Gou, Q., Yang, F., Zeng, N., et al. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa602 · Cited by 16 · cited 1×
“A mAb cocktail containing the 4 antibodies could prevent MRSA252 infection by reducing bacterial burden and pathogenicity (Zeng et al. 2021).”
BackgroundNatali, E. N., Principato, S., Ferlicca, F., Bianchi, F., Fontana, L. E., Faleri, A., Pansegrau, W., Surdo, P. L., Bartolini, E., Santini, L., et al. (2020) · The FASEB Journal · doi:10.1096/fj.201902795r · Cited by 15 · cited 4×
“The Fc region of antigen-bound antibodies can bind to C1q, thereby triggering the classical complement pathway to lyse bacteria through the formation of a membrane attack complex (MAC) (McConnell 2019; Natali et al.”
BackgroundInfluentialRapid Detection of Staphylococcal Enterotoxin-B by Lateral Flow Assay
Hnasko, R. M., Lin, A. V., & McGarvey, J. A. (2019) · Monoclonal Antibodies in Immunodiagnosis and Immunotherapy · doi:10.1089/mab.2019.0028 · Cited by 15
Antibodies to Conserved Surface Polysaccharides Protect Mice Against Bacterial Conjunctivitis
Zaidi, T., Zaidi, T. H., & Pier, G. B. (2018) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.18-23795 · Cited by 11 · cited 1×
“reported in 2018 that an IgG1 mAb against alginate could reduce inflammatory cells infiltration, pathological corneal damage, and bacterial load level (Zaidi et al. 2018).”
BackgroundCao, J., Yi, F., Qiu-feng, T. I. A. N., Dang, G., Si, W., Liu, S., & Yu, S. (2017) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1337613 · Cited by 10
Sundin, C., Saleeb, M., Spjut, S., Qin, L., & Elofsson, M. (2021) · Biomolecules · doi:10.3390/biom11010055 · Cited by 8
Gao, F., Zhai, G., Wang, H., Lu, L., Xu, J., Zhu, J., Chen, D., & Lu, H. (2020) · Microbial Pathogenesis · doi:10.1016/j.micpath.2020.104240 · Cited by 7
Self-citationHuang, B., Xie, T., Rotstein, D. S., Fang, H., & Frucht, D. M. (2015) · Toxins · doi:10.3390/toxins7103960 · Cited by 6
François, B., Sanchez, M. G., Eggimann, P., Dequin, P., Laterre, P. F., Huberlant, V., Escudero, D., Boulain, T., Bretonnière, C., Pugin, J., et al. (2019) · doi:10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a7358 · Cited by 6
Neutralization of the anthrax toxin by antibody-mediated stapling of its membrane-penetrating loop
Hoelzgen, F., Zalk, R., Alcalay, R., Cohen-Schwartz, S., Garau, G., Shahar, A., Mazor, O., & Frank, G. A. (2021) · Acta Crystallographica Section D Structural Biology · doi:10.1107/s2059798321007816 · Cited by 5
Monoclonal antibodies and bacterial virulence
Luciani, M., & Iannetti, L. (2017) · Virulence · doi:10.1080/21505594.2017.1292199 · Cited by 4 · cited 1×
“Monoclonal antibodies (mAbs) have lower variability, higher specificity, and less cross-reaction with host cells and normal flora than polyclonal antisera (Berry and Gaudet 2011; Luciani and Iannetti 2017; Zurawski and McLendon 2020).”
BackgroundIndividuelle Therapiestrategien bei Clostridium-difficile-Infektionen
Solbach, P., Dersch, P., & Bachmann, O. P. (2017) · Der Internist · doi:10.1007/s00108-017-0268-2 · Cited by 4
Bezlotoxumab for the Prevention of Clostridium difficile Recurrence
Chahine, E. B., Cho, J. C., & Worley, M. V. (2018) · The Consultant Pharmacist · doi:10.4140/tcp.n.2018.89 · Cited by 4
Cited by
Alternative therapeutic strategies to treat antibiotic-resistant pathogens
MacNair, C. R., Rutherford, S. T., & Tan, M.-W. (2024) · Nature Reviews Microbiology · doi:10.1038/s41579-023-00993-0 · Cited by 276
“…targeting the Staphylococcus aureus α-toxin failed to reduce the infection in pneumonia 61 ; however, additional toxin-neutralizing or virulence factor-neutralizing mAbs are in various stages of clinical development, highlighting the perceived utility of these molecules to help patients 53,62,63 .”
Antibody–Antimicrobial Conjugates for Combating Antibiotic Resistance
Yu, L., Shang, Z., Jin, Q., Chan, S. Y., Hong, W., Li, N., & Li, P. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202202207 · Cited by 41
Qin, J., Li, J., Pei, H., Li, Q., Cheng, D., Zhou, J., Pei, G., Wang, Y., & Liu, F. (2024) · Environmental Technology & Innovation · doi:10.1016/j.eti.2024.103649 · Cited by 32
Nanomaterials as multimodal photothermal agents (PTAs) against ‘Superbugs’
Roy, S., Roy, J., & Guo, B. (2023) · Journal of Materials Chemistry B · doi:10.1039/d2tb02396b · Cited by 31
Esposito, S., Amirthalingam, G., Bassetti, M., Blasi, F., Rosa, F. G. D., Halasa, N., Hung, I. F., Osterhaus, A. D. M. E., Tan, T. Q., Torres, J. P., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1162342 · Cited by 36
Metadata
- Authors
- Wang, H., Chen, D., & Lu, H.
- Affiliations
- Shanghai Jiao Tong University (CN)
- Corresponding author
- Lu, Huili
- Venue
- Applied Microbiology and Biotechnology
- Published
- 2022-06
- Volume
- 106
- Issue
- 11
- Pages
- 3957-3972
- ISSN
- 0175-7598 (ISSN-L)
- 1432-0614
- OpenAlex
- W4281685120
- Cited by
- 45
- References
- 122
- Citations by year
- 2026: 11 · 2025: 11 · 2024: 12 · 2023: 8 · 2022: 3
- FWCI
- 1.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Applied Microbiology and Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Keywords
- antibiotic resistance, bacterial toxins, virulence factor inhibition, complement-mediated killing, opsonic phagocytosis, bacterial surface components, antibiotic therapy
- MeSH terms
- Anti-Bacterial Agents, Antibodies, Bacterial, Antibodies, Monoclonal, Bacteria, Bacterial Infections, Humans
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.